A practical reference on reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-12. Anything still debated is marked as such rather than presented as settled.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
The doctor who had ordered the tests was a diabetes expert who specialised in insulin and hypoglycaemic episodes, and she had believed the incident to be suspicious. No doctor or medical staff member had prescribed her this drug, and she had no condition that required it to be issued. The amount of insulin in Hall's blood was about 12 times the normal level, and it had been injected into her system. The insulin was manufactured and not produced naturally in the body. It had been injected into her abdomen, as indicated by the fact that a bulge was found under her skin there that was consistent with a large injection of fluid. Doctors believed it was done by someone with nursing or medical experience. The results of the tests led the hospital to contact the police. It was discovered after Hall's death that insulin had also been taken from the storage fridge, and Norris later admitted that he was the last person to have accessed this fridge before Hall had been injected with insulin. Two vials of insulin were found to have been taken from the fridge, which had to have been taken by someone during the night shift which Norris was working when Hall became unwell. Norris had on a previous occasion been caught stealing drugs from the hospital. Norris also admitted that he was the last person to see Hall at 4.30 am, half an hour before she fell into the hypoglycaemic coma. at around 5 am.
=== Pharmacokinetics === Vasopressin is administered through an intravenous device, intramuscular injection or a subcutaneous injection. The duration of action depends on the mode of administration and ranges from thirty minutes to two hours. It has a half life of ten to twenty minutes. It is widely distributed throughout the body and remains in the extracellular fluid. It is degraded by the liver and excreted through the kidneys. Arginin vasopressins for use in septic shock are intended for intravenous use only.
=== Some roles in development === Since G protein–coupled receptors are known to activate Signal transduction in cells, it should not be surprising to find MC1R involved in development. As one example at the cellular level, preventing signalling by MC1R stopped erythropoiesis from proceeding from the polychromatic cell stage (poly-E in the figure) to the orthochromatic cell stage (ortho-E in the diagram). The same report showed that neutralizing antibodies to MC1R prevented phosphorylation of STAT5 by erythropoietin, and that MC2R and MC5R were also involved, as shown in their model.
The two substrates of this enzyme are fluorenol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are fluorenone, reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is fluoren-9-ol:NAD(P)+ oxidoreductase. This enzyme participates in fluorene degradation.
Sources: en.wikipedia.org
== Further reading == National Academies of Sciences, Engineering, and Medicine (2019). A Research Agenda for Transforming Separation Science (Report). Washington, DC: The National Academies Press. doi:10.17226/25421. ISBN 978-0-309-49170-9.{{cite report}}: CS1 maint: multiple names: authors list (link)
Center for Strategic and International Studies (CSIS) specialist Clayton Seigle said oil companies sought stability in Venezuela above all else, adding that the outlook for US interests in the country remained uncertain. Another CSIS expert, Christopher Hernandez-Roy, said Trump's reluctance to engage in full regime change was driven by fear of chaos, noting that, aside from Maduro's removal, the current regime remained unchanged. American political analyst David Rothkopf described President Trump's conduct as the "Putinization of US foreign policy". Analysts Ryan C. Berg and Alexander B. Gray stated that the action showed a robust commitment to Trump's 2025 National Security Strategy (NSS) and a desire to increase preeminence in the Western Hemisphere, in turn signaling a "global reestablishment of deterrence" to countries such as China, alluding to the latter's investments in Venezuela. Atlantic Council Counterterrorism Project head Alex Plitsas urged an orderly transition, warning that instability in Venezuela could lead to political fragmentation and criminal violence involving colectivo gangs; Berg elaborated that any systemic change would likely be lengthy, while reinforcing the Trump administration's "America First" agenda. Indian political analyst Brahma Chellaney argued that while the legal framing (drug trafficking charges) resembles the 1989 invasion of Panama and the seizure of Manuel Noriega, the actual methodology and strategic narrative align more closely with the 2003 invasion of Iraq.
While research accelerators had once generated 70 percent of sales, industrial products now accounted for 80 percent. Despite the strategic pivot, HVEC struggled to achieve sustained profitability. Its subsidiaries faced intense competition from larger conglomerates. In 1981, HVEC divested from its accelerator manufacturing business. Two years later, it sold its Burlington manufacturing plant. The company refocused on smaller industrial products including specialty plastics, wire, industrial instruments, and electrical connectors. Through the 1980s, HVEC progressively sold these product lines to other manufacturing conglomerates. In 1988, private equity firm Hyde Park Partners bid to take HVEC private at roughly twice its prevailing share price. Though Levesque resisted, shareholders accepted the offer in 1989. Hyde Park dismissed existing management, sold remaining real estate, and relocated the headquarters to Charlestown, Massachusetts. The company filed for bankruptcy in 2005. Since 2019, corporate remnants have been held by Oak Point Partners.
Sources: en.wikipedia.org
=== Interpretation of results === Laboratory results may differ depending on the analytical technique, the age of the subject, and biological variation among individuals. Higher levels of HbA1c are found in people with persistently elevated blood sugar, as in diabetes mellitus. While diabetic patients' treatment goals vary, many include a target range of HbA1c values. A diabetic person with good glucose control has an HbA1c level that is close to or within the reference range. The International Diabetes Federation and the American College of Endocrinology recommend HbA1c values below 48 mmol/mol (6.5 DCCT %), while the American Diabetes Association recommends HbA1c be below 53 mmol/mol (7.0 DCCT %) for most patients. Results from large trials in 2008–09 suggested that a target below 53 mmol/mol (7.0 DCCT %) for older adults with type 2 diabetes may be excessive: Below 53 mmol/mol, the health benefits of reduced A1c become smaller, and the intensive glycemic control required to reach this level leads to an increased rate of dangerous hypoglycemic episodes. A retrospective study of 47,970 type 2 diabetes patients, aged 50 years and older, found that patients with an HbA1c more than 48 mmol/mol (6.5 DCCT %) had an increased mortality rate, but a later international study contradicted these findings.
== Applications == The primary use of DMF is as a solvent with low evaporation rate. DMF is used in the production of acrylic fibers and plastics. It is also used as a solvent in peptide coupling for pharmaceuticals, in the development and production of pesticides, and in the manufacture of adhesives, synthetic leathers, fibers, films, and surface coatings.
In order to attain a concentration that makes sense with the data, the dilutions, concentrations, and units of the unknown must be normalized (Table 1). To do this, one must divide concentration by volume of protein in order to normalize concentration and multiply by amount diluted to correct for any dilution made in the protein before performing the assay.
== Epidemiology == The prevalence of VWD is about one in 100 individuals. However, the majority of these people do not have symptoms. The prevalence of clinically significant cases is one per 10,000. Because most forms are rather mild, they are detected more often in women, whose bleeding tendency shows during menstruation. It may be more severe or apparent in people with blood type O.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.